Insider BuyCUE· · June 3, 2026, 9:31 PM UTC
Cue Biopharma CEO buys $1M of stock at a 70 DEHY Score
A chief executive’s open-market purchase clears one of the higher conviction marks of the week.
Shao-Lee Lin, chief executive of Cue Biopharma, disclosed a roughly $1M open-market purchase of CUE that scored a 70 on the DEHY Score — high for a small-cap biotech buy. CEO purchases at this conviction level are precisely what the score is built to surface ahead of the noise.
Reporting insider: Lin Shao-Lee · Chief Executive Officer · discretionary, open-market
The filing, structured
| Security | Date | Type | Shares | Price | Owned after | Holding |
|---|---|---|---|---|---|---|
| Pre-Funded Warrants (Right to Buy) | 2026-06-01 | Open-market purchase | +91K | $11.00 | 91K | Indirect |
| Common Stock Warrants (Right to Buy) | 2026-06-01 | Open-market purchase | +45K | — | 45K | Indirect |
FAQ
- What insider transaction did Cue Biopharma, Inc. (CUE) report?
- Shao-Lee Lin, chief executive of Cue Biopharma, disclosed a roughly $1M open-market purchase of CUE that scored a 70 on the DEHY Score — high for a small-cap biotech buy. CEO purchases at this conviction level are precisely what the score is built to surface ahead of the noise.
- Who made the purchase at $CUE?
- Lin Shao-Lee, Chief Executive Officer, is the reporting insider on this Form 4, a purchase of about $1000K.
- Was the $CUE trade an open-market transaction or a 10b5-1 plan?
- The trade was a discretionary, open-market transaction — not executed under a pre-arranged 10b5-1 plan.
- What is the DEHY Score for this $CUE filing?
- This filing scored 70 out of 100 on the DEHY Score, a 0–100 triage signal for how much analyst attention a filing warrants — not a price prediction.
Structured from public SEC data within seconds of filing. The DEHY Score is a 0–100 triage signal, not investment advice or a price prediction. See methodology.